FoundationOne Liquid is the first and only liquid biopsy test to show prospective clinical utility in a global, registrational trial for patients with newly diagnosed, metastatic non-small cell lung cancer (NSCLC).1

Submit an order online, by email, or via fax.

If you have questions, we are here to help. Call Foundation Medicine Client Services at (888) 988-3639 between 8:00 am ET and 8:00 pm ET, Monday through Friday. You can also send us an email to client.services@foundationmedicine.com and a representative will respond during regular business hours.

Ordering Overview

To order a Foundation Medicine test for a patient

Order Online - for faster order processing

  1. Login or sign up for a Foundation Medicine account
  2. Complete the online form
  3. Provide required attachments - the online form will inform you if an Advance Beneficiary Notice (ABN) is likely required based on the information you provide, but you can learn more here
  4. Submit

Order by Email

  1. Download and complete a Test Requisition Form. Follow instructions here for filling out the form
  2. Gather attachments - pathology report, insurance information, and Advance Beneficiary Notice (ABN) if required (learn more about when ABNs may be required here)
  3. Email the requisition form along with attachments to client.services@foundationmedicine.com

You can also place an order via fax by sending a completed test requisition form along with attachments to 617-418-2290.

To order a specimen kit for any of our tests

Please contact a Client Services Representative at (888) 988-3639 or client.services@foundationmedicine.com.

If sending a solid tumor specimen, Foundation Medicine will complete the rest of the specimen retrieval process. We will contact the pathologist and send a Specimen Collection Kit with instructions for sample procurement and shipment.

If sending peripheral blood or bone marrow aspirate, please follow the specimen preparation instructions for liquid specimens.

International Customers

To order, please visit rochefoundationmedicine.com or call +1 (888) 988-3639.

FoundationOne®CDx

FDA-approved broad companion diagnostic (CDx) for solid tumors with Medicare coverage for qualifying patients1

Patients with solid tumors can be tested with FoundationOne CDx, our only FDA-approved test, which is performed on formalin-fixed paraffin embedded (FFPE) specimens, including cut slide specimens.

When submitting specimens to Foundation Medicine, please include the following items in the FoundationOne CDx Specimen Kit:

  • Appropriate specimen per FoundationOne CDx Specimen Instructions labeled with two patient-specific identifiers
  • Completed Test Requisition Form
  • Copy of recent pathology/cytology reports
  • If needed, an Advance Beneficiary Notice signed by the patient (learn more about when this is required here)


1 Medicare and Medicare Advantage members have coverage of FoundationOne CDx in accordance with the Centers for Medicare and Medicaid Services (CMS) national coverage determination (NCD) criteria.

In-depth test results are typically available online or via fax in less than two weeks from receipt of specimen. Reports may help match cancer patients’ genomic profile with applicable targeted therapies, immunotherapies, and clinical trials to expand treatment options.


FoundationOne®Liquid

Patients with solid tumors can also be tested using our laboratory developed liquid biopsy test, FoundationOne Liquid, which requires two tubes of peripheral whole blood. When submitting specimens to Foundation Medicine, please include the following items in the FoundationOne Liquid Specimen Kit:

  • Appropriate specimen per FoundationOne Liquid Specimen Collection Instructions (use only blood tubes provided in the kit)
  • Completed Test Requisition Form
  • If needed, an Advance Beneficiary Notice signed by the patient (learn more about when this is required here)

In-depth test results are typically available online or via fax in less than two weeks from receipt of specimen. Reports may help match cancer patients’ genomic profiles with targeted therapies, immunotherapies, and clinical trials to expand treatment options.

FoundationOne Liquid was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Liquid has not been cleared or approved by the U.S. Food and Drug Administration. For more information on FoundationOne Liquid please see its Technical Specifications at www.foundationmedicine.com.

FoundationOne®Heme

Patients with hematologic malignancies, sarcomas, or solid tumors where RNA sequencing is desired, can be tested with our laboratory developed test,FoundationOne Heme, which can be performed on FFPE, peripheral whole blood or bone marrow aspirate specimens. When submitting specimens to Foundation Medicine, please include the following items in the FoundationOne Heme Specimen Kit:

  • Appropriate specimen per FoundationOne Heme Specimen Collection Instructions, labeled with two patient-specific identifiers
  • Completed Test Requisition Form
  • Copy of recent pathology/cytology reports
  • If needed, an Advance Beneficiary Notice signed by the patient (learn more about when this is required here)

Note for Bone Samples: DO NOT USE strong acids (e.g. hydrochloric acid, sulfuric acid, picric acid) as these destroy nucleic acid. When decalcification is required, the use of EDTA is recommended.

In-depth test results are typically available online or via fax in approximately two weeks from receipt of specimen. Reports may help match cancer patients’ genomic profile with targeted therapies, immunotherapies, and clinical trials to expand treatment options.

FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine. FoundationOne Heme has not been cleared or approved by the U.S. Food and Drug Administration. For more information about FoundationOne Heme, please see its Technical Specifications at www.foundationmedicine.com.

IHC Testing

Foundation Medicine offers two antibodies to test for PD-L1 expression:

  • Dako 22C3
  • Ventana SP142

Scoring and clone utilization for PD-L1 testing is based on FDA-approved indications. Please download the list of “IHC PD-L1 FDA-Approved Companion Diagnostics” for more information.

PD-L1 Dako 22C3 pharmDx is a qualitative immunohistochemical assay using monoclonal mouse anti-PD-L1 clone 22C3 intended for use in the detection of PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue from multiple tumor types in accordance with the approved product labeling.

PD-L1 Ventana SP142 is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) tissue in accordance with the approved product labeling.

For breast cancer cases PD-L1 testing will be performed using the Ventana SP142 assay unless otherwise requested.

For tumors with no CDx indication, Foundation Medicine will perform PD-L1 testing using the Dako PD-L1 22C3 PharmDx assay.

For Urothelial Carcinoma (URC), if PD-L1 testing with the Ventana SP142 clone is preferred, please indicate that preference on the test requisition form, via online ordering, or contact our client services team at +1 888.988.3639 or by email at client.services@foundationmedicine.com.